Clavius (amoxicillin, clavulanic acid)

875 mg + 125 mg film-coated tablets
500 mg filmom obložene tablete

We have enriched our portfolio of antibiotics with our first penicillin in the product range, amoxicillin (aminopenicillin acting against gram positive and gram negative bacteria, and anaerobes) in combination with clavulanic acid, a beta-lactamase inhibitor. This well known combination is also known as co-amoxiclav.

Co-amoxiclav treatment is suitable for the treatment of many infections (acute bacterial sinusitis, acute otitis media, acute exacerbations of chronic bronchitis, community-acquired pneumonia, cystitis, pyelonephritis, skin and soft tissue infections, bone and joint infections), and according to the ISKRA guidelines, it is the first drug of choice in the outpatient treatment of recurrent infections of streptococcal pharyngitis, acute uncomplicated pyelonephritis, and complicated urinary tract infections.

The drug is indicated for adults and children over 40 kg.

Clavius is a prescription drug that is included in the primary list of drugs of the Croatian Health Insurance Fund (CHIF).

JADRAN - GALENSKI LABORATORIJ dd issued this content on 26 January 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 10 February 2016 16:50:09 UTC

Original Document: http://www.jgl.hr/en/news-and-the-media/news/new-antibiotic-in-the-portfolio-of-prescription-medicines-1/